Home » Reports » USA Broker Ratings » BioMarin Pharmaceutical Inc. 22.2% Potential Upside Now Implied by Morgan Stanley
Company Interviews

BioMarin Pharmaceutical Inc. 22.2% Potential Upside Now Implied by Morgan Stanley

BioMarin Pharmaceutical Inc. using SYMBOL/TICKER code NASDAQ:BMRN has had its stock rating noted as ‘Initiated’ with the recommendation being set at ‘OVERWEIGHT’ yesterday by analysts at Morgan Stanley. BioMarin Pharmaceutical Inc. are listed in the Health Care sector within NASDAQ. Morgan Stanley have set their target price at 110 USD on its stock. This indicates the analyst believes there is a potential upside of 22.2% from the opening price of 90 USD.



BioMarin Pharmaceutical Inc. NASDAQ:BMRN has a 50 day moving average of 86.71 USD and a 200 Day Moving Average share price is recorded at 89.91 USD. The 1 year high stock price is 102.49 USD while the year low stock price is currently 62.12 USD. Over the last 30 and 90 trading days the company share price has increased 6.94 points and decreased 3.08 points respectively. There are currently 171,851,931 shares in issue with the average daily volume traded being 1,084,160. Market capitalisation for NASDAQ:BMRN is $15,279,355,815.00 USD.


BioMarin Pharmaceutical Inc. develops and commercializes pharmaceuticals for various diseases and medical conditions. The Company’s product portfolio consists of approximately five approved products, and multiple clinical and pre-clinical product candidates. Its approved products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate).

You might also find these articles of interest:

Register here to be notified of future articles like this
Get all our broker ratings on Twitter as they are published!